67 results about "Enalapril" patented technology

The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and/or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.

Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.

The invention discloses a composition containing a dihydropyridine calcium channel blocker and a preparation method thereof and relates to a sustained-release preparation of felodipine, which comprises felodipine which is dihydropyridine calcium channel blocker and function as an active ingredient, enalapril which is angiotensin converting enzyme inhibitor, as well as a slow release material, a filling agent and a lubricating agent which function as auxiliary materials; wherein the slow release material contains hydroxypropyl methylcellulose. As the enalapril which is angiotensin converting enzyme inhibitor is added in coating solution, the curative effect of the sustained-release preparation is improved.

The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and cardiology. In one aspect, the invention provides compositions comprising enalapril and simvastatin for use in methods for the treatment and/or prevention of cardiovascular disease, and to the use of such compositions in the manufacture of products for such treatment and/or prevention. In another aspect, the invention provides methods for the treatment and/or prevention of cardiovascular disease using compositions comprising enalapril, simvastatin and acetylsalicylic acid. The compositions and methods of the invention are useful in the treatment and prevention of cardiovascular disease in a variety of animals, particularly humans.

The invention relates to a kind of chemosynthesis method of N-[1(S)-ethoxy carbonyl-3-phenyl propyl]-L-alanine-N-hydroxy acid anhydride, which is the medicine midbody for synthesizing Pulitzer series medicine such as Enalapril, Ramipril, Lisinopril and so on. The invention uses couple (trichloromethyl) ester carbonate and N-[1(S)-ethoxy carbonyl-3-phenyl propyl]-L-alanine as row material, and get the product by reacting with catalyst action in organic solvent. This chemosynthesis method is a manufacturing method of N-[1(S)-ethoxy carbonyl-3-phenyl propyl]-L-alanine-N-hydroxy acid anhydride, which has acquirable raw material, low production cost, and no three wastes normally.

Methods and kits are provided for detecting polymorphisms in carboxylesterase-1 (CES1). Several single nucleotide polymorphisms (SNPs) in CES1 in humans, and methods for detecting the same, are provided (e.g., Gly143Glu, 12754T>del). Results indicate that the Gly143Glu (9486G>A) polymorphism has an allelic frequency of 1.5% in the Caucasian population. Polymorphisms of the present invention may alter the function of the carboxylesterase-1 enzyme (hCES1). Thus, the methods and kits of the present invention may be used to personalize a therapy and/or avoid adverse consequences of altered metabolism of a therapeutic or compound (e.g., enalapril, methylphenidate, etc.) which may result due to a CES1 polymorphism. In addition, recombinant cells lines overexpressing wild-type CES1 or expressing CES1 mutants are provided. Such cell lines may be used to assess the effects of candidate compounds on CES1, and the action of CES1 on these candidate compounds.

According to the conception of a novel drug design, the present invention provides improved decoration based on the existing ACEI and relates to a design comprising the following two types of conception: first, the toxic side-effect points of the existing ACEI are avoided to the greatest extent; secondly, the effects of the ACEI are improved to the greatest extent. Thus the present invention provides a novel ACEI compound. Based on the basic structure of enalapril, the present invention provides a synthetic route for improving decoration. The structure of propanamine-sulfonyl is changed into cattle sulphonyl; the praline is changed into timonacic acid and derivatives thereof, so as to prepare a series of compounds, namely, N-[2-(1-ethoxycarbonyl-3-phenylalanine)-cattle-sulfonyl]-timonacic acid and derivatives thereof. The drugs are screened to prepare novel high-efficiency and low-toxicity ACEI.

The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.

The invention relates to an enalapril (Enalapril) cutaneous penetration preparation which is used for delivering enalapril in a therapeutic dose to a human body through skin and serves as a new enalapril dosage form for treating hypertension. The enalapril (Enalapril) cutaneous penetration preparation comprises a three-layer structure, namely a backing layer, a drug storage layer and a release layer. The formula provided by the invention comprises a provided transdermal absorption enhancer. The enalapril (Enalapril) cutaneous penetration can be prepared.

The invention relates to a tablet composition containing enalapril and folic acid and a preparation method thereof. The tablets prepared by the preparation method are capable of effectively reducing the degradation of active ingredients of a medicine while improving the stability and safety of a compound solid preparation as well as the disintegration rate and timeliness of the medicine in the stomach and intestines; the composition meets the dosage requirements for accurate absorption, and the therapeutic effect of the medicine is remarkably improved.

The invention relates to a medicament composition preparation comprising an Enalapril quick-releasing part and a felodipine slow-releasing part. The medicament composition is a medical composition formed by mixing Enalapril and felodipine as medical active components with and pharmaceutically acceptable auxiliary materials. The composition preparation comprising comprises a slow-releasing part tablet core and a quick-releasing part coating, wherein the slow-releasing part tablet core is the felodipine, and the quick-releasing part coating is the Enalapril or Enalapril-acid addition salts. Thecomposition can rapidly stabilize blood pressure and permanently keep the blood pressure steady.

The present invention provides a method for treatment of diabetes, comprising administering a pitavastatin, and in combination therewith, enalapril or a salt thereof.

The invention relates to a hypotensive compound preparation consisting of bevantolol or pharmaceutical salt thereof and enalapril or pharmaceutical salt thereof, wherein in the preparation, the enalapril or the pharmaceutical salt thereof is a fast release part, and the bevantolol or the pharmaceutical salt thereof is a sustained release part. The compound preparation, for moderate and severe hypertension patients, has strong hypotensive effect, sustained action, convenient administration for patients, and accurate dosage.

The invention relates to an external application patch containing enalapril and a preparation method thereof. Enalapril is used as the main medicine of the external application patch and used for treating high blood pressure. According to the external application patch containing the enalapril, medicine release is even through transdermal absorption, the action is moderate and durable, the external application patch directly acts on the skin and will not be absorbed through the gastrointestinal tract, the first pass effect of the liver is avoided, adverse effects are reduced, and the occurrence rate of the adverse effects is reduced. The compliance of a patient is good, and the external application patch is convenient to use and carry.

The present invention relates to a medicine composition containing enalapril or benazepril and sotalol. It is a new type hypotensor medicine composition. The content of enalapril or benazepril is 5-40 mg and the sotalol content is 20-160mg.

The invention relates to a pharmaceutical composition comprising an angiotensin converting enzyme inhibitor (ACEI), an enkephalinase inhibitor, a folic acid compound and a pharmaceutically acceptable carrier, wherein the ACEI is selected from the group consisting of enalapril, benazepril, ramipril, fosinopril, cilazapril, perindopril and the like, and the content is 1.25-75 mg; the enkephalinase inhibitor is sacubitril, and the content is 10-120 mg; and the folic acid compound is selected from the group consisting of folic acid, 5-methyltetrahydrofolate, calcium formyltetrahydrofolate, leucovorin, calcium levofolinate and the like, and the content is 0.1-5 mg. The invention provides the use of the pharmaceutical composition in the preparation of a medicament for the treatment of chronic heart failure and the prevention of stroke. By the implementation of the invention, the pharmaceutical composition can also improve the compliance of patients and improve the therapeutic effect by providing the pharmaceutical composition for a specific use to the patients.

The invention provides a primary hypertension elastomer subcutaneous implant rod. The primary hypertension elastomer subcutaneous implant rod comprises, by weight, 100 to 200 parts of polycaprolactone, 70 to 200 parts of polyethylene glycol, 15 to 20 parts of polyvinylpyrrolidone, and 100 to 180 parts of bulk drug. The bulk drug is composed of enalapril, lacidipine, and irbesartan at a mass ratioof 1:1:1.6. The degradation time of the primary hypertension elastomer subcutaneous implant rod is long; drug effect lasts long; clinical treatment of hypertension can be realized; side effect causedby long term of eating of drugs is reduced; risk caused by missed doses of drugs is avoided; and the primary hypertension elastomer subcutaneous implant rod is mainly used for clinical treatment of primary hypertension.

The invention discloses a pharmaceutical composition for treating hypertensive left ventricular hypertrophy; the pharmaceutical composition comprises total glucosides of paeony and at least one angiotensin converting enzyme inhibitor; the angiotensin converting enzyme inhibitor is captopril, enalapril, perindopril or fosinopril. The pharmaceutical composition has very significant reverse effect on hypertension induced ventricular hypertrophy; by adopting the pharmaceutical composition, the perfect synergy function on each index such as left ventricular index of myocardial hypertrophy is obtained.

An angiotensin converting enzyme (ACE) inhibitor is mainly used for treating diseases such as hypertension, congestive heart failure, myocardial infarction, renal dysfunction, etc. The existing medicines in the market comprise captopril, enalapril, benazepril, and the like, which have obvious adverse reactions such as severe dry cough, parageusia, proteinuria, hematuria, hypotension, and the like, and the medicines have some adverse reactions that threaten life such as acute thrombocytopenia, hyperkalemia, severe arrhythmia and renal failure. The invention relates to a technical scheme for chemosynthesis of a 2-alkoxycarbonyl-3-phenylpropionic acid ester derivative with the characteristic of the structural general formula I and provides a 2-alkoxycarbonyl-3-phenylpropionic acid ester derivative with the characteristic of the structural general formula I and the derivative is taken as an ACE inhibitor for treating diseases such as hypertension, congestive heart failure, myocardial infarction and renal dysfunction, and lowering blood sugar and blood lipid, etc. R1, R2, R3 and R4 are -H, C1-3-alkyl, C1-3-alkenylnyl, C1-3-alkoxy, aryloxy, arylalkoxyl, heterocycles, heteroarylalkyl, acyl, acyloxy, hydroxy C1-3-alkyl, hydroxy, amino, halogen, nitro, cyano, formyl, acylamino, C1-3-alkyamino, C1-3-alkoxycarbonylamino, C1-3-alkylcarbonylamino, C1-3-alkylsulfonyl and arylsulfonyl.

The invention relates to a medicinal composition for lowering blood pressure, which consists of trichlormethiazide and angiotensin converting enzyme inhibitor which serve as active ingredients and a pharmaceutical carrier, wherein the angiotensin converting enzyme inhibitor may be enalapril, cilazapril, benazepril, captopril, ramipril, perindopril and fosinopril. The unit dosage of trichlormethiazide is 0.5 to 8 milligrams, preferably 2 to 4 milligrams. The unit dosage of angiotensin converting enzyme inhibitor is 1.5 to 50 milligrams. The medicinal composition can be made into various oral preparations including conventional tablets, capsules, chewable tablets, dispersible tablets and effervescent tablets.